Literature DB >> 2112091

Growth hormone deficiency in children: role of magnetic resonance imaging in assessing aetiopathogenesis and prognosis in idiopathic hypopituitarism.

C Pellini1, B di Natale, R De Angelis, N Bressani, G Scotti, F Triulzi, G Chiumello.   

Abstract

To search for the presence of morphostructural abnormalities of the hypothalamus-pituitary region in growth hormone deficient (GHD) children magnetic resonance imaging (MRI) was performed in 30 GHD patients (age 10.09 +/- 3.5 years) and in 15 healthy age-matched controls. MRI demonstrated a significantly small sella and pituitary volume compared to controls and normal literatures values. In 20 patients the structures were extremely small and an abnormal development of the pituitary stalk was observed, and in 18 of these patients the bright spot indicating the neurohypophysis was dislocated to the distal part of the maldeveloped stalk, although these children had a normal fluid balance. From a functional point of view hypothalamus and pituitary defects were equally distributed between the two morphological groups. The patients with multiple endocrine defects had the smallest pituitary volume and abnormal stalk. A possible pathogenetic role of perinatal trauma or dysembryogenic events are discussed. A careful follow up of patients with isolated GHD presenting MRI abnormalities of the pituitary is suggested for the possible evolution in panhypopituitarism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112091     DOI: 10.1007/bf01957687

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  27 in total

1.  The volume of the sella turcica.

Authors:  G DI CHIRO; K B NELSON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-06

2.  High-resolution MR imaging of pituitary microadenomas at 1.5 T: experience with Cushing disease.

Authors:  W W Peck; W P Dillon; D Norman; T H Newton; C B Wilson
Journal:  AJR Am J Roentgenol       Date:  1989-01       Impact factor: 3.959

3.  Posterior pituitary gland: appearance on MR images in normal and pathologic states.

Authors:  N Colombo; I Berry; J Kucharczyk; W Kucharczyk; J de Groot; T Larson; D Norman; T H Newton
Journal:  Radiology       Date:  1987-11       Impact factor: 11.105

4.  Transection of the pituitary stalk: development of an ectopic posterior lobe assessed with MR imaging.

Authors:  I Fujisawa; K Kikuchi; K Nishimura; K Togashi; K Itoh; S Noma; S Minami; T Sagoh; T Hiraoka; T Momoi
Journal:  Radiology       Date:  1987-11       Impact factor: 11.105

5.  New standards for the assessment of sella turcica volume in children.

Authors:  L E Underwood; W B Radcliffe; F C Guinto
Journal:  Radiology       Date:  1976-06       Impact factor: 11.105

6.  Growth hormone (GH) response to a single intravenous injection of synthetic GH-releasing hormone in prepubertal children with growth failure.

Authors:  P Chatelain; Y Alamercery; J Blanchard; J P Boissel; D Evain-Brion; M Morre; M Olivier; P Sizonenko; G Van Vliet
Journal:  J Clin Endocrinol Metab       Date:  1987-09       Impact factor: 5.958

7.  Plasma growth hormone (GH) response to GH-releasing factor in normal children with short stature and patients with pituitary dwarfism.

Authors:  K Takano; N Hizuka; K Shizume; K Asakawa; M Miyakawa; N Hirose; T Shibasaki; N C Ling
Journal:  J Clin Endocrinol Metab       Date:  1984-02       Impact factor: 5.958

8.  Dysgenesis of the corpus callosum and hypopituitarism.

Authors:  P J Smith; P Hindmarsh; B Kendall; C G Brook
Journal:  Acta Paediatr Scand       Date:  1986-11

9.  Idiopathic growth hormone (GH) deficiency, and GH deficiency secondary to hypothalamic germinoma: effect of single and repeated administration of human GH-releasing factor (hGRF) on plasma GH level and endogenous hGRF-like immunoreactivity level in cerebrospinal fluid.

Authors:  K Chihara; Y Kashio; H Abe; N Minamitani; H Kaji; T Kita; T Fujita
Journal:  J Clin Endocrinol Metab       Date:  1985-02       Impact factor: 5.958

10.  The primary empty sella syndrome: analysis of the clinical characteristics, radiographic features, pituitary function and cerebrospinal fluid adenohypophysial hormone concentrations.

Authors:  R M Jordan; J W Kendall; C W Kerber
Journal:  Am J Med       Date:  1977-04       Impact factor: 4.965

View more
  8 in total

Review 1.  Neuroendocrine imaging.

Authors:  D J Seidenwurm
Journal:  AJNR Am J Neuroradiol       Date:  2008-03       Impact factor: 3.825

2.  Magnetic resonance imaging in idiopathic hypopituitarism.

Authors:  P M Doraiswamy; D A Axelson; P R Escalona; S A Shah; M M Husain; G S Figiel; K R Krishnan
Journal:  Eur J Pediatr       Date:  1991-06       Impact factor: 3.183

3.  Dystopic neurohypophysis.

Authors:  Faruk Aydin; INitya R Ghatak
Journal:  Endocr Pathol       Date:  1994-03       Impact factor: 3.943

4.  Sequential contrast-enhanced magnetic resonance imaging in the diagnosis of growth hormone deficiencies.

Authors:  A Liotta; C Maggio; M Giuffrè; M Carta; L Manfrè
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

5.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

6.  Pituitary hypoplasia in patients with a mutation in the growth hormone-releasing hormone receptor gene.

Authors:  R A Murray; H G Maheshwari; E J Russell; G Baumann
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

7.  Abnormal development of the sella turcica and lack of pituitary visualization in a patient with partial hypopituitarism.

Authors:  M Scacchi; G Alé; P Silvestri; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

Review 8.  Isolated growth hormone deficiency.

Authors:  Libia M Hernández; Phillip D K Lee; Cecilia Camacho-Hübner
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.